EANS-News: Intercell AG Intercell and Vivalis provide update on the progress
towards intended merger
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Company Information
Wien (euro adhoc) - Nantes (France) and Vienna (Austria), January 28, 2013 - On
16 December 2012, Vivalis SA ("Vivalis") and Intercell AG ("Intercell")
announced their intention to merge and form Valneva SE ("Valneva"). The merger
is progressing well, in line with the timeline communicated at time of
announcement:
* The French merger document (Document E) has been registered by the Autorité
des marchés financiers (AMF) on 23 January 2013
* The full set of applicable merger documents have been made available on
Intercell and Vivalis websites
* Intercell and Vivalis General Meetings have been convened and will take place
on 27 February 2013 and 4 March 2013 respectively
* Merger is expected to close in May 2013, after which Valneva intends to launch
a EUR 40 million capital increase, subject to regulatory approval
Additionally, Vivalis and Intercell have finalized the proposed governance of
Valneva, agreeing on the following initial Supervisory Board (Conseil de
Surveillance) composition:
* Frédéric Grimaud (Chairman), Alain Munoz and Michel Gréco proposed by Vivalis
* Prof. Alexander von Gabain, James Sulat, and Prof. Hans Wigzell proposed by
Intercell
* Anne-Marie Graffin proposed by the Fonds Stratégique d'Investissement ("FSI"),
to be nominated upon closing of the planned capital increase
In addition to the listing of Valneva Ordinary Shares on NYSE Euronext Paris and
on the Vienna Stock Exchange, Vivalis and Intercell have decided to also apply
for the listing of the Preferred Shares on Euronext Paris, upon completion of
the merger.
Thomas Lingelbach, future President and Chief Executive Officer of Valneva, and
Franck Grimaud, future President and Chief Business Officer commented: "We are
extremely pleased with the progress made on the merger and are moving according
to our planned timeline. We expect the merger to close in May and are ready and
very enthusiastic about the next phase."
Further inquiry note:
Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime
stockmarkets: official market: Wien
language: English
Company Information Wien (euro adhoc) - Vienna (Austria), December 19, 2012 - Intercell AG (VSE; "ICLL") today announced that the CHMP of the European Medicines Agency (EMA) has come to a positive opinion on the Marketing Authorisation for IXIARO® in children, a vaccine to protect against Japanese Encephalitis ...
9-month report 07.11.2012 » IXIARO®/JESPECT® - product sales growth trend continues despite lower than expected product sales of EUR 3.5m in Q3 2012 » U.S. military places largest IXIARO® order to date in Q4 2012 » Net loss for Q3 2012 slightly decreased by 2.8% to EUR 7.5m Q3 2012 Financial results » Total revenues decreased by 41.3% to EUR 4.4m in Q3 2012 ...